In acute ischemic stroke patients, Cerebrolysin produced a more rapid stroke-volume decrease by day 28 than placebo (45.4% versus 43.6%, p < 0.05).
In plain wordsIn acute ischemic stroke patients, Cerebrolysin reduced stroke volume more rapidly than placebo by day 28.
- Peptide
- Cerebrolysin
- Outcome
- DecreaseStroke lesion volume reduction by day 28
- Study
n = 47
- Comparator
- Placebo
- Outcome group
- Neuroprotection · Nervous system and cognition
- Studied dose
- 50 mlAs given in this study (human).
Measurements
- Stroke volume decrease
- 45.4%
- Cerebrolysin
- Stroke volume decrease
- 43.6%
- Placebo
- p value for stroke volume decrease comparison
- < 0.05
- Cerebrolysin versus placebo, day 28
Source sentences
A quantitative time-related MRI analysis of the dynamics of neurological deficit revealed the more rapid decrease of stroke volume to the 28th day in the group treated with cerebrolysin (45.4% versus 43.6% in the placebo-group (p < 0.05)).
2 context sentences(design, population, supporting numbers)
The purpose of this randomized, double-blind, placebo-controlled study was to assess safety and efficacy of cerebrolysin used in dosage 50 ml in acute ischemic stroke.
Forty-seven patients with ischemic stroke, aged 45-85 years, who were admitted to a clinical unit within the first 12 h after stroke onset were included in the study.